The promotion and marketing of oxycontin: commercial triumph, public health tragedy.
I focus on issues surrounding the promotion and marketing of controlled drugs and their regulatory oversight. Compared with noncontrolled drugs, controlled drugs, with their potential for abuse and diversion, pose different public health risks when they are overpromoted and highly prescribed. An in-depth analysis of the promotion and marketing of OxyContin illustrates some of the associated issues. Modifications of the promotion and marketing of controlled drugs by the pharmaceutical industry and an enhanced capacity of the Food and Drug Administration to regulate and monitor such promotion can have a positive impact on the public health.
Van Zee
Art
A
Stone Mountain Health Services, St Charles Clinic, St Charles, VA 24282, USA. artvanzee@adelphia.net
D000701:Analgesics, Opioid; D003132:Commerce; D004345:Drug Industry; D006801:Humans; D040541:Marketing / Q000458:organization & administration; D010098:Oxycodone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010565:Persuasive Communication; D011634:Public Health; D019966:Substance-Related Disorders; D014481:United States; D014486:United States Food and Drug Administration
D000701:Analgesics, Opioid; D010098:Oxycodone
Arch Intern Med. 2000 Mar 27;160(6):853-60
10737286
J Gen Intern Med. 2002 Mar;17(3):173-9
11929502
South Med J. 2006 Nov;99(11):1245-55
17195420
J Pain Symptom Manage. 2004 Aug;28(2):176-88
15276196
Pharmacoepidemiol Drug Saf. 2006 Sep;15(9):618-27
16862602
Pharmacotherapy. 2002 Jul;22(7):898-904
12126222
Ann Intern Med. 2007 Jan 16;146(2):116-27
17227935
Int J Addict. 1995 Jun;30(8):919-27
7558484
Pain. 1997 Oct;73(1):37-45
9414055
Ann Intern Med. 2007 May 15;146(10):751-2
17502637
Neurology. 2003 Mar 25;60(6):927-34
12654955
Lancet. 1996 Jan 20;347(8995):143-7
8544547
Arch Gen Psychiatry. 1984 Oct;41(10):934-41
6089692
Clin J Pain. 2007 Feb;23(2):173-9
17237667
Clin J Pain. 1999 Sep;15(3):179-83
10524470
J Pain. 2005 Oct;6(10):662-72
16202959
Drug Alcohol Depend. 2006 Feb 1;81(2):103-7
16023304
Clin J Pain. 2007 May;23(4):303-6
17449990
Neurology. 1998 Jun;50(6):1837-41
9633737
Am J Public Health. 2006 Oct;96(10):1755-7
17008568
Clin J Pain. 1997 Jun;13(2):150-5
9186022
Cancer. 1990 Dec 15;66(12):2642-4
2249204
Med Lett Drugs Ther. 2001 Sep 17;43(1113):80-1
11581580
Chest. 1992 Jul;102(1):270-3
1623766
Pain. 1995 Aug;62(2):169-178
8545142
J Pain Symptom Manage. 2002 Apr;23(4):278-91
11997197
Pain. 1990 Dec;43(3):309-318
2293142
J Clin Pharmacol. 2001 May;41(5):500-6
11361046
Anesth Analg. 2003 Oct;97(4):1097-1102
14500164
J Psychosom Res. 1997 Nov;43(5):497-504
9394266
Eur J Pain. 1998;2(3):239-49
15102384
Pain. 1982 Jul;13(3):267-280
6126853
N Engl J Med. 1980 Jan 10;302(2):123
7350425
J Clin Oncol. 1998 Oct;16(10):3230-7
9779696
Spine (Phila Pa 1976). 1998 Dec 1;23(23):2591-600
9854758
J Rheumatol. 1999 Apr;26(4):862-9
10229408
Eur J Pain. 2007 Jul;11(5):490-518
17070082
J Pain Symptom Manage. 1998 Apr;15(4):244-52
9601160
Pain. 2001 Feb 1;90(1-2):47-55
11166969
N Engl J Med. 2003 Mar 27;348(13):1223-32
12660386
N Y Times Web. 2000 Nov 16;:A1, A22
12159839
J Pain Symptom Manage. 2003 Nov;26(5):1026-48
14585554
Neurology. 2002 Oct 8;59(7):1015-21
12370455
J Clin Oncol. 1998 Oct;16(10):3222-9
9779695
Clin J Pain. 1992 Jun;8(2):77-85
1633386
J Rheumatol. 2000 Mar;27(3):764-71
10743822